Complete Filing Data
Amylyx Pharmaceuticals, Inc. reported Stockholders Equity of $305.26 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Amylyx Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$144.7M | -$301.7M | $49.3M | -$198.4M | -$87.9M |
| Revenue * | $0.00 | $87.4M | $380.8M | $22.2M | $285.0K |
| Other Comprehensive Income Loss Amortization Adjustment From AOCI Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax | $496.0K | -$289.0K | $283.0K | -$95.0K | $9.0K |
| Research And Development Expense | $90.4M | $104.1M | $128.2M | $93.5M | $44.0M |
| Other Nonoperating Income Expense | -$700.0K | -$1.2M | -$660.0K | -$551.0K | -$51.0K |
| Operating Income Loss | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M |
| Nonoperating Income Expense | $8.6M | $12.6M | $15.5M | $3.7M | -$5.2M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$144.7M | -$302.1M | $54.3M | -$197.6M | -$87.9M |
| Comprehensive Income Net Of Tax | -$144.2M | -$302.0M | $49.6M | -$198.5M | -$87.9M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $496.0K | -$289.0K | $283.0K | -$95.0K | $9.0K |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $627.0K | -$396.0K | $188.0K | -$69.0K | $14.0K |
| Selling General And Administrative Expense | $62.9M | $114.3M | $188.4M | $127.1M | $38.9M |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | $95.0K | -$26.0K | -$5.0K | ||
| Income Tax Expense Benefit | $46.0K | -$393.0K | $5.0M | $774.0K | |
| Cost Of Goods And Services Sold | $0.00 | $6.0M | $25.4M | $3.0M | |
| Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments | $0.00 | $118.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$34.4M | -$41.4M | -$35.9M | -$72.7M | -$72.7M | -$118.8M | $20.9M | $22.1M | $1.6M | -$53.8M | -$54.1M | -$47.8M | -$23.1M | -$21.9M | -$14.5M |
| Revenue * | $0.00 | $0.00 | $0.00 | $416.0K | -$1.0M | $88.6M | $102.7M | $98.2M | $71.4M | $345.0K | $285.0K | ||||
| Other Comprehensive Income Loss Amortization Adjustment From AOCI Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax | $264.0K | $551.0K | $92.0K | $738.0K | -$20.0K | -$274.0K | -$79.0K | -$97.0K | $111.0K | -$529.0K | -$45.0K | -$160.0K | -$1.0K | ||
| Research And Development Expense | $19.9M | $27.2M | $22.1M | $21.2M | $23.3M | $36.6M | $30.0M | $29.0M | $24.2M | $24.9M | $24.3M | $21.5M | $12.9M | $10.9M | $6.9M |
| Other Nonoperating Income Expense | -$180.0K | -$546.0K | -$335.0K | -$141.0K | -$483.0K | -$747.0K | -$488.0K | -$81.0K | -$262.0K | $199.0K | -$42.0K | -$19.0K | -$227.0K | -$26.0K | $261.0K |
| Operating Income Loss | -$36.0M | -$42.9M | -$37.8M | -$75.7M | -$76.3M | -$122.1M | $18.7M | $20.2M | -$2.1M | -$54.7M | -$54.3M | -$47.8M | -$22.9M | -$18.6M | -$12.9M |
| Nonoperating Income Expense | $1.6M | $1.4M | $1.9M | $3.0M | $3.6M | $3.6M | $3.7M | $3.8M | $3.5M | $800.0K | $360.0K | $112.0K | -$224.0K | -$3.3M | -$1.7M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$34.4M | -$41.4M | -$35.9M | -$72.7M | -$72.7M | -$118.6M | $22.4M | $24.0M | $1.4M | -$53.9M | -$53.9M | -$47.7M | -$23.1M | -$21.9M | -$14.5M |
| Comprehensive Income Net Of Tax | -$34.1M | -$40.9M | -$35.8M | -$72.0M | -$72.7M | -$119.1M | $20.8M | $22.0M | $1.7M | -$54.3M | -$54.1M | -$48.0M | -$23.1M | -$21.9M | -$14.5M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $265.0K | $551.0K | $92.0K | $738.0K | -$20.0K | -$274.0K | -$79.0K | -$97.0K | $111.0K | -$529.0K | -$45.0K | -$160.0K | -$1.0K | ||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $176.0K | $627.0K | $249.0K | $301.0K | -$43.0K | -$158.0K | -$138.0K | -$18.0K | $79.0K | -$559.0K | $58.0K | -$68.0K | $4.0K | ||
| Selling General And Administrative Expense | $16.2M | $15.6M | $15.7M | $17.8M | $21.6M | $57.8M | $48.7M | $43.4M | $44.0M | $29.9M | $30.0M | $26.4M | $10.4M | ||
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | $89.0K | -$76.0K | -$157.0K | $437.0K | $23.0K | -$116.0K | $59.0K | -$79.0K | $32.0K | $30.0K | -$103.0K | -$92.0K | -$5.0K | ||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $242.0K | $1.5M | $1.9M | -$170.0K | -$125.0K | $174.0K | $146.0K | |||
| Cost Of Goods And Services Sold | $0.00 | $0.00 | $0.00 | $0.00 | $8.0K | $5.9M | $5.2M | $5.6M | $5.3M | $172.0K | |||||
| Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments | $0.00 | $0.00 | $0.00 | $809.0K | $7.4M | $110.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $305.3M | $164.8M | $433.4M | $340.6M | -$151.2M | -$66.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $227.6M | $78.8M | $170.9M | $63.2M | $50.4M | $13.1M |
| Operating Lease Right Of Use Asset | $5.2M | $1.8M | $3.7M | $5.5M | $5.0M | |
| Cash And Cash Equivalents At Carrying Value | $226.7M | $77.4M | $170.2M | $62.5M | $50.2M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $148.8M | -$92.1M | $107.7M | $12.9M | $37.3M | |
| Retained Earnings Accumulated Deficit | -$751.4M | -$606.7M | -$304.9M | -$354.2M | -$155.8M | |
| Property Plant And Equipment Net | $310.0K | $961.0K | $2.7M | $2.6M | $474.0K | |
| Prepaid Expense And Other Assets Current | $6.6M | $12.5M | $14.9M | $10.1M | $5.4M | |
| Liabilities Current | $22.7M | $28.4M | $82.0M | $46.6M | $17.4M | |
| Liabilities And Stockholders Equity | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M | |
| Liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M | |
| Common Stock Value | $11.0K | $7.0K | $7.0K | $7.0K | $1.0K | |
| Assets Current | $323.7M | $189.4M | $464.7M | $382.1M | $105.0M | |
| Assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M | |
| Additional Paid In Capital Common Stock | $1.06B | $771.5M | $738.2M | $694.9M | $4.7M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $404.0K | -$92.0K | $197.0K | -$86.0K | $9.0K | |
| Accounts Payable Current | $3.5M | $2.9M | $22.1M | $6.3M | $4.4M | |
| Accretion Amortization Of Discounts And Premiums Investments | $5.5M | $9.9M | $9.9M | $2.1M | -$121.0K | |
| Operating Lease Liability Noncurrent | $4.7M | $463.0K | $2.0M | $4.2M | ||
| Operating Lease Liability Current | $1.3M | $1.5M | $2.3M | $2.0M | ||
| Restricted Cash Equivalents Noncurrent | $985.0K | $1.4M | $719.0K | $719.0K | $189.0K | |
| Accounts Receivable Net Current | $88.0K | $447.0K | $40.1M | $15.3M | ||
| Other Assets Noncurrent | $701.0K | $466.0K | ||||
| Accrued Liabilities Current | $17.9M | $23.9M | $57.7M | $38.3M | ||
| Purchases Of Property And Equipment Included In Accounts Payable | $0.00 | $20.0K | $98.0K | $22.0K | ||
| Short Term Investments | $284.4M | $45.9M | ||||
| Taxes Withheld On Stock Based Awards Included In Accrued Expenses | $2.0K | $23.0K | ||||
| Unrealized Gain Loss On Investments | $95.0K | -$26.0K | -$5.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $332.0M | $167.9M | $201.4M | $196.2M | $261.3M | $324.4M | $418.4M | $386.4M | $352.6M | $144.0M | $192.8M | $240.9M | -$124.1M | -$101.9M | -$80.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $226.2M | $59.5M | $61.2M | $73.3M | $75.7M | $171.3M | $136.0M | $248.5M | $115.3M | $108.5M | $67.9M | $110.8M | $76.9M | $15.3M | $26.3M | ||
| Operating Lease Right Of Use Asset | $5.5M | $5.8M | $1.3M | $5.1M | $2.8M | $3.3M | $4.2M | $4.6M | $5.1M | $6.0M | $6.4M | $6.8M | |||||
| Cash And Cash Equivalents At Carrying Value | $225.2M | $58.1M | $59.8M | $71.8M | $75.0M | $170.6M | $135.3M | $247.8M | $114.6M | $107.7M | $67.4M | $110.4M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$17.6M | $351.0K | $52.0M | $60.4M | $13.3M | ||||||||||||
| Retained Earnings Accumulated Deficit | -$718.4M | -$684.0M | -$642.6M | -$569.1M | -$496.4M | -$423.7M | -$309.7M | -$330.6M | -$352.6M | -$311.5M | -$257.8M | -$203.7M | |||||
| Property Plant And Equipment Net | $399.0K | $445.0K | $816.0K | $1.3M | $1.5M | $2.5M | $2.8M | $2.6M | $2.6M | $2.1M | $1.9M | $1.3M | |||||
| Prepaid Expense And Other Assets Current | $9.3M | $6.0M | $11.8M | $9.1M | $12.8M | $16.9M | $17.3M | $11.8M | $12.7M | $8.3M | $9.5M | $10.3M | |||||
| Liabilities Current | $25.8M | $21.4M | $17.9M | $53.9M | $70.1M | $91.6M | $45.6M | $64.1M | $51.6M | $32.6M | $27.2M | $27.7M | |||||
| Liabilities And Stockholders Equity | $362.7M | $194.6M | $219.7M | $250.7M | $332.2M | $417.5M | $466.6M | $453.6M | $408.0M | $181.4M | $225.2M | $274.4M | |||||
| Liabilities | $30.7M | $26.7M | $18.3M | $54.5M | $70.9M | $93.0M | $48.2M | $67.2M | $55.3M | $37.4M | $32.5M | $33.5M | |||||
| Common Stock Value | $11.0K | $9.0K | $9.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | $6.0K | |||||
| Assets Current | $353.4M | $186.9M | $216.1M | $245.3M | $326.7M | $410.5M | $434.1M | $427.4M | $389.1M | $172.2M | $216.1M | $265.5M | |||||
| Assets | $362.7M | $194.6M | $219.7M | $250.7M | $332.2M | $417.5M | $466.6M | $453.6M | $408.0M | $181.4M | $225.2M | $274.4M | |||||
| Additional Paid In Capital Common Stock | $1.05B | $851.4M | $844.0M | $764.7M | $757.8M | $748.2M | $728.2M | $717.0M | $705.3M | $456.3M | $450.7M | $444.8M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $815.0K | $551.0K | $0.00 | $641.0K | -$97.0K | -$77.0K | -$151.0K | -$72.0K | $25.0K | -$725.0K | -$196.0K | -$151.0K | |||||
| Accounts Payable Current | $5.3M | $3.3M | $4.8M | $1.5M | $5.0M | $21.5M | $6.4M | $24.7M | $10.8M | $7.1M | $8.1M | $10.0M | |||||
| Accretion Amortization Of Discounts And Premiums Investments | $1.7M | $2.6M | $2.9M | -$2.0K | |||||||||||||
| Operating Lease Liability Noncurrent | $5.0M | $5.3M | $327.0K | $595.0K | $772.0K | $1.4M | $2.6M | $3.1M | $3.7M | $4.8M | $5.3M | $5.8M | |||||
| Operating Lease Liability Current | $981.0K | $665.0K | $1.1M | $2.0M | $2.4M | $2.3M | $2.2M | $2.1M | $2.1M | $2.0M | $1.8M | $1.4M | |||||
| Restricted Cash Equivalents Noncurrent | $983.0K | $1.5M | $1.4M | $1.4M | $719.0K | $719.0K | $719.0K | $719.0K | $719.0K | ||||||||
| Accounts Receivable Net Current | $132.0K | $103.0K | $300.0K | $1.7M | $4.1M | $20.4M | $29.4M | $33.5M | $17.6M | $137.0K | |||||||
| Other Assets Noncurrent | $2.5M | $11.0K | $24.0K | $482.0K | $479.0K | $493.0K | $476.0K | $466.0K | $466.0K | $456.0K | $456.0K | $456.0K | |||||
| Accrued Liabilities Current | $19.5M | $17.5M | $12.1M | $50.5M | $62.8M | $67.9M | $37.0M | $37.2M | $38.8M | ||||||||
| Purchases Of Property And Equipment Included In Accounts Payable | $63.0K | $509.0K | |||||||||||||||
| Short Term Investments | $234.8M | $202.7M | $201.2M | $219.8M | $109.5M | $231.1M | $54.9M | $139.2M | $144.8M | ||||||||
| Taxes Withheld On Stock Based Awards Included In Accrued Expenses | $30.0K | $9.0K | $22.0K | ||||||||||||||
| Unrealized Gain Loss On Investments | -$32.0K | $92.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $27.6M | $33.0M | $37.2M | $21.7M | $3.1M |
| Payments To Acquire Property Plant And Equipment | $138.0K | $157.0K | $1.2M | $2.5M | $353.0K |
| Net Cash Provided By Used In Operating Activities | -$123.3M | -$167.6M | $11.9M | -$179.9M | -$74.8M |
| Net Cash Provided By Used In Investing Activities | $14.0M | $75.7M | $92.1M | -$239.0M | -$46.4M |
| Net Cash Provided By Used In Financing Activities | $257.0M | $348.0K | $3.5M | $431.8M | $158.5M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$6.0M | -$2.0M | $3.2M | $5.2M | $4.5M |
| Increase Decrease In Accounts Payable | $580.0K | -$19.1M | $15.9M | $1.9M | $670.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.1M | -$438.0K | $160.0K | -$65.0K | $13.0K |
| Payments To Acquire Investments | $231.8M | $232.0M | $300.8M | $415.9M | $49.1M |
| Proceeds From Sale And Maturity Of Marketable Securities | $246.0M | $344.0M | $394.1M | $179.4M | $3.0M |
| Increase Decrease In Accrued Interest Receivable Net | -$24.0K | -$359.0K | -$23.0K | -$487.0K | $144.0K |
| Increase Decrease In Operating Lease Liability | -$1.2M | -$2.3M | -$2.0M | -$917.0K | |
| Increase Decrease In Operating Lease Right Of Use Assets | $1.7M | $2.0M | $1.8M | $1.6M | |
| Increase Decrease In Other Operating Assets | $231.0K | $456.0K | -$125.0K | ||
| Increase Decrease In Accounts Receivable | -$359.0K | -$39.6M | $24.7M | $15.3M | |
| Increase Decrease In Accrued Liabilities | -$6.6M | -$59.8M | $21.6M | ||
| Increase Decrease In Inventories | $9.3M | $73.1M | $9.8M | ||
| Proceeds From Exercise Of Stock Options And Restricted Stock Units Vesting | $4.1M | $2.1M | $7.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $6.8M | $9.9M | $7.5M | $4.4M | $586.0K |
| Payments To Acquire Property Plant And Equipment | $11.0K | $67.0K | $250.0K | $342.0K | $14.0K |
| Net Cash Provided By Used In Operating Activities | -$39.8M | -$489.0K | -$5.1M | -$40.6M | -$12.6M |
| Net Cash Provided By Used In Investing Activities | -$43.7M | $819.0K | $56.0M | -$99.3M | -$14.0K |
| Net Cash Provided By Used In Financing Activities | $65.7M | $131.0K | $1.0M | $200.5M | $25.9M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$666.0K | $2.1M | $2.9M | $4.9M | $244.0K |
| Increase Decrease In Accounts Payable | $1.9M | -$652.0K | $4.6M | $5.0M | $177.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $197.0K | -$110.0K | $75.0K | -$68.0K | |
| Payments To Acquire Investments | $103.6M | $73.1M | $9.8M | $123.9M | |
| Proceeds From Sale And Maturity Of Marketable Securities | $60.0M | $74.0M | $66.0M | $24.9M | |
| Increase Decrease In Accrued Interest Receivable Net | -$66.0K | -$117.0K | -$253.0K | $1.0K | $2.0K |
| Increase Decrease In Operating Lease Liability | -$599.0K | -$543.0K | -$491.0K | -$3.0K | |
| Increase Decrease In Operating Lease Right Of Use Assets | $515.0K | $473.0K | $436.0K | $374.0K | |
| Increase Decrease In Other Operating Assets | -$13.0K | -$204.0K | $456.0K | -$102.0K | |
| Increase Decrease In Accounts Receivable | -$147.0K | -$19.7M | $2.2M | ||
| Increase Decrease In Accrued Liabilities | -$11.9M | -$7.8M | $2.2M | $2.7M | |
| Increase Decrease In Inventories | $0.00 | $9.3M | $13.3M | ||
| Proceeds From Exercise Of Stock Options And Restricted Stock Units Vesting | $970.0K | $1.4M | $3.5M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Diluted EPS * | -$1.53 | -$4.43 | $0.70 | -$3.39 | -$13.35 |
| Weighted Average Number Of Shares Outstanding Basic | 94.6M | 68.1M | 67.2M | 58.5M | 6.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 94.6M | 68.1M | 70.0M | 58.5M | 6.6M |
| Earnings Per Share Basic | $-1.53 | $-4.43 | $0.73 | $-3.39 | $-13.35 |
| Common Stock Shares Issued | 109.9M | 68.6M | 67.7M | 66.5M | 7.0M |
| Common Stock Shares Outstanding | 109.9M | 68.6M | 67.7M | 66.5M | 7.0M |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 56.5M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 10.0M | 0.00 | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.37 | -$0.46 | -$0.42 | -$1.07 | -$1.07 | -$1.75 | $0.30 | $0.31 | $0.02 | -$0.92 | -$0.93 | -$0.93 | -$3.42 | -$3.41 | -$2.33 | ||
| Weighted Average Number Of Shares Outstanding Basic | 93.3M | 89.1M | 85.7M | 68.1M | 68.0M | 67.9M | 67.4M | 67.2M | 66.7M | 58.5M | 58.3M | 51.6M | 6.8M | 6.4M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 93.3M | 89.1M | 85.7M | 68.1M | 68.0M | 67.9M | 69.7M | 70.1M | 70.9M | 58.5M | 58.3M | 51.6M | 6.8M | 6.4M | |||
| Earnings Per Share Basic | $-0.37 | $-0.46 | $-0.42 | $-1.07 | $-1.07 | $-1.75 | $0.31 | $0.33 | $0.02 | $-0.92 | $-0.93 | $-0.93 | $-3.42 | $-3.41 | |||
| Common Stock Shares Issued | 109.8M | 89.2M | 89.1M | 68.5M | 68.1M | 68.0M | 67.5M | 67.4M | 67.1M | 58.5M | 58.5M | 57.9M | |||||
| Common Stock Shares Outstanding | 109.8M | 89.2M | 89.1M | 68.5M | 68.1M | 68.0M | 67.5M | 67.4M | 67.1M | 58.5M | 58.5M | 57.9M | |||||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $27.6M | $33.0M | $37.5M | $21.7M | $3.1M |
| Stock Issued During Period Value Stock Options Exercised | $774.0K | $327.0K | $5.7M | $2.2M | $343.0K |
| Investment Income Interest | $9.3M | $13.8M | $16.2M | $4.3M | $36.0K |
| Costs And Expenses | $153.3M | $402.1M | $342.0M | $223.6M | $83.0M |
| Depreciation | $525.0K | $904.0K | $1.1M | $487.0K | $52.0K |
| Withholding Taxes Paid On Stock Based Awards | $3.4M | $1.8M | $3.3M | ||
| Stock Issued During Period Shares Stock Options Exercised | 213.1K | 210.1K | 1.0M | 950.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $7.1M | $7.4M | $6.8M | $6.8M | $9.6M | $9.9M | $10.3M | $10.1M | $7.6M | $5.5M | $5.7M | $4.4M | $802.0K | $657.0K | $586.0K |
| Stock Issued During Period Value Stock Options Exercised | $428.0K | $2.0K | $57.0K | $57.0K | $23.0K | $147.0K | $938.0K | $1.7M | $2.8M | $248.0K | $196.4M | $164.0K | $3.0K | $31.0K | |
| Investment Income Interest | $1.8M | $2.0M | $2.2M | $3.1M | $4.1M | $4.3M | $4.2M | $3.9M | $3.7M | $601.0K | $402.0K | $131.0K | $3.0K | $1.0K | $2.0K |
| Costs And Expenses | $36.0M | $42.9M | $37.8M | $76.1M | $75.3M | $210.8M | $84.0M | $78.0M | $73.5M | $55.0M | $54.3M | $47.8M | $23.2M | ||
| Depreciation | $156.0K | $315.0K | $204.0K | $35.0K | $10.0K | ||||||||||
| Withholding Taxes Paid On Stock Based Awards | $885.0K | $1.3M | $2.4M | ||||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 36.3K | 49.6K | 451.3K | 669.0K |
Most recent annual filing with the SEC: March 3, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.